Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.

Waheed W, Ayer GA, Jadoo CL, Badger GJ, Aboukhatwa M, Brannagan TH 3rd, Tandan R.

Muscle Nerve. 2019 Aug 23. doi: 10.1002/mus.26678. [Epub ahead of print]

PMID:
31443119
2.

Demyelinating Neuropathy in a Patient Treated With Revusiran for Transthyretin (Thr60Ala) Amyloidosis.

Zanazzi G, Arshad M, Maurer MS, Brannagan TH 3rd, Tanji K.

J Clin Neuromuscul Dis. 2019 Mar;20(3):120-128. doi: 10.1097/CND.0000000000000242.

3.

Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis.

Buxbaum JN, Brannagan T 3rd, Buades-Reinés J, Cisneros E, Conceicao I, Kyriakides T, Merlini G, Obici L, Plante-Bordeneuve V, Rousseau A, Sekijima Y, Imai A, Waddington Cruz M, Yamada M.

Amyloid. 2019 Mar;26(1):10-14. doi: 10.1080/13506129.2018.1554563. Epub 2019 Jan 24.

PMID:
30675806
4.

Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.

Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH 3rd, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O.

Circulation. 2019 Jan 22;139(4):431-443. doi: 10.1161/CIRCULATIONAHA.118.035831.

PMID:
30586695
5.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

6.

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB.

N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.

7.

Celiac disease and risk of myasthenia gravis - nationwide population-based study.

Thawani SP, Brannagan TH, Lebwohl B, Green PHR, Ludvigsson JF.

BMC Neurol. 2018 Mar 12;18(1):28. doi: 10.1186/s12883-018-1035-2.

8.

Type 1 Diabetes, Celiac Disease, and Neuropathy-A Nationwide Cohort Study.

Thawani S, Brannagan TH 3rd, Lebwohl B, Mollazadegan K, Green PHR, Ludvigsson JF.

J Clin Neuromuscul Dis. 2017 Sep;19(1):12-18. doi: 10.1097/CND.0000000000000174.

PMID:
28827484
9.

Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Dyck PJ, Kincaid JC, Dyck PJB, Chaudhry V, Goyal NA, Alves C, Salhi H, Wiesman JF, Labeyrie C, Robinson-Papp J, Cardoso M, Laura M, Ruzhansky K, Cortese A, Brannagan TH 3rd, Khoury J, Khella S, Waddington-Cruz M, Ferreira J, Wang AK, Pinto MV, Ayache SS, Benson MD, Berk JL, Coelho T, Polydefkis M, Gorevic P, Adams DH, Plante-Bordeneuve V, Whelan C, Merlini G, Heitner S, Drachman BM, Conceição I, Klein CJ, Gertz MA, Ackermann EJ, Hughes SG, Mauermann ML, Bergemann R, Lodermeier KA, Davies JL, Carter RE, Litchy WJ.

Muscle Nerve. 2017 Nov;56(5):901-911. doi: 10.1002/mus.25563. Epub 2017 Apr 7.

10.

Reply.

Farhad K, Brannagan TH 3rd.

Muscle Nerve. 2017 Feb;55(2):291. doi: 10.1002/mus.25427. Epub 2016 Nov 4. No abstract available.

PMID:
27701749
11.

REPLY.

Farhad K, Brannagan TH 3rd.

Muscle Nerve. 2016 Nov;54(5):983-984. doi: 10.1002/mus.25237. Epub 2016 Jul 17. No abstract available.

PMID:
27389826
12.

Evaluation of patients with refractory chronic inflammatory demyelinating polyneuropathy.

Kaplan A, Brannagan TH 3rd.

Muscle Nerve. 2017 Apr;55(4):476-482. doi: 10.1002/mus.25271. Epub 2016 Dec 23.

PMID:
27463215
13.

Rapidly Progressive Transthyretin-Mediated Amyloidosis in a Domino Liver Transplant Recipient of a Ser23Asn Donor.

Dixit N, Castano A, Farr MJ, Traub R, Lentzsch S, Brown RS Jr, Maurer MS, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2016 Mar;17(3):142-5. doi: 10.1097/CND.0000000000000110.

PMID:
26905915
14.

Amifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.

Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrnić D, Shieh PB, Vial C, Meisel A, Komoly S, Schoser B, Sivakumar K, So Y; LEMS Study Group.

Muscle Nerve. 2016 May;53(5):717-25. doi: 10.1002/mus.25070. Epub 2016 Mar 3.

PMID:
26852139
15.

Construction and validation of the chronic acquired polyneuropathy patient-reported index (CAP-PRI): A disease-specific, health-related quality-of-life instrument.

Gwathmey KG, Conaway MR, Sadjadi R, Joshi A, Barnett C, Bril V, Ng E, David W, Gable K, Guptill JT, Hobson-Webb LD, Dineen J, Hehir M, Brannagan TH 3rd, Byun E, Adler M, Burns TM.

Muscle Nerve. 2016 Jun;54(1):9-17. doi: 10.1002/mus.24985. Epub 2015 Dec 29.

16.

Causes of neuropathy in patients referred as "idiopathic neuropathy".

Farhad K, Traub R, Ruzhansky KM, Brannagan TH 3rd.

Muscle Nerve. 2016 Jun;53(6):856-61. doi: 10.1002/mus.24969. Epub 2015 Dec 29.

PMID:
26561790
17.

Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies.

Leitch MM, Sherman WH, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2015 Sep;17(1):1-5. doi: 10.1097/CND.0000000000000083.

PMID:
26301372
18.

Neuromuscular complications of hematopoietic stem cell transplantation.

Ruzhansky KM, Brannagan TH 3rd.

Muscle Nerve. 2015 Oct;52(4):480-7. doi: 10.1002/mus.24724. Epub 2015 Aug 19. Review.

PMID:
26044357
19.

Treatment of chronic inflammatory demyelinating polyneuropathy.

Kleyman I, Brannagan TH 3rd.

Curr Neurol Neurosci Rep. 2015 Jul;15(7):47. doi: 10.1007/s11910-015-0563-z. Review.

PMID:
26008811
20.

Bortezomib-associated demyelinating neuropathy--clinical and pathologic features.

Thawani SP, Tanji K, De Sousa EA, Weimer LH, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2015 Jun;16(4):202-9. doi: 10.1097/CND.0000000000000077.

PMID:
25996966
21.

Risk of Neuropathy Among 28,232 Patients With Biopsy-Verified Celiac Disease.

Thawani SP, Brannagan TH 3rd, Lebwohl B, Green PH, Ludvigsson JF.

JAMA Neurol. 2015 Jul;72(7):806-11. doi: 10.1001/jamaneurol.2015.0475.

PMID:
25962148
22.

Discordant phenotype in monozygotic female twins with Lys35Thr TTR familial amyloidotic polyneuropathy.

Ruzhansky K, Scoon J, Weimer LH, Maurer MS, Berk JL, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2014 Sep;16(1):1-6. doi: 10.1097/CND.0000000000000040.

PMID:
25137508
23.

Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.

Goldman JS, Quinzii C, Dunning-Broadbent J, Waters C, Mitsumoto H, Brannagan TH 3rd, Cosentino S, Huey ED, Nagy P, Kuo SH.

JAMA Neurol. 2014 Jun;71(6):771-4. doi: 10.1001/jamaneurol.2013.5762.

24.

Quality improvement in neurology: Distal symmetric polyneuropathy quality measures.

England JD, Franklin G, Gjorvad G, Swain-Eng R, Brannagan TH 3rd, David WS, Dubinsky RM, Smith BE.

Neurology. 2014 May 13;82(19):1745-8. doi: 10.1212/WNL.0000000000000397. Epub 2014 Apr 2.

25.

Increased expression of the receptor for advanced glycation end-products in human peripheral neuropathies.

Juranek JK, Kothary P, Mehra A, Hays A, Brannagan TH 3rd, Schmidt AM.

Brain Behav. 2013 Nov;3(6):701-9. doi: 10.1002/brb3.176. Epub 2013 Oct 8.

26.

Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy.

Breiner A, Brannagan TH 3rd.

Muscle Nerve. 2014 Jul;50(1):40-6. doi: 10.1002/mus.24088. Epub 2013 Dec 11.

PMID:
24338746
27.

Intravenous immunoglobulin for treatment of neuromuscular disease.

Ruzhansky K, Brannagan TH 3rd.

Neurol Clin Pract. 2013 Oct;3(5):440-445. doi: 10.1212/CPJ.0b013e3182a78ecf.

28.

Reduced expression of Munc13-1 in human and porcine diabetic peripheral nerve.

Juranek JK, Geddis MS, Kothary P, Hays A, Schmidt AM, Brannagan TH 3rd.

Acta Histochem. 2014 Jan;116(1):106-11. doi: 10.1016/j.acthis.2013.05.010. Epub 2013 Jul 5.

PMID:
23830992
29.

RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice.

Juranek JK, Geddis MS, Song F, Zhang J, Garcia J, Rosario R, Yan SF, Brannagan TH, Schmidt AM.

Diabetes. 2013 Mar;62(3):931-43. doi: 10.2337/db12-0632. Epub 2012 Nov 19.

30.

Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide.

Leitch MM, Sherman WH, Brannagan TH 3rd.

Muscle Nerve. 2013 Feb;47(2):292-6. doi: 10.1002/mus.23629. Epub 2012 Nov 21.

PMID:
23168526
31.

Copper levels in patients with celiac neuropathy.

Patterson SK, Green PH, Tennyson CA, Lewis SK, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2012 Sep;14(1):11-6. doi: 10.1097/CND.0b013e318260b455.

PMID:
22922576
32.

Current issues in peripheral neuropathy.

Brannagan TH 3rd.

J Peripher Nerv Syst. 2012 May;17 Suppl 2:1-3. doi: 10.1111/j.1529-8027.2012.00387.x. Review.

PMID:
22548615
33.

Peripheral neuropathic symptoms in celiac disease and inflammatory bowel disease.

Shen TC, Lebwohl B, Verma H, Kumta N, Tennyson C, Lewis S, Scherl E, Swaminath A, Capiak KM, DiGiacomo D, Bosworth BP, Brannagan TH 3rd, Green PH.

J Clin Neuromuscul Dis. 2012 Mar;13(3):137-45. doi: 10.1097/CND.0b013e31821c55a1.

PMID:
22538308
34.

Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review.

Castaño A, Bokhari S, Brannagan TH 3rd, Wynn J, Maurer MS.

Amyloid. 2012 Mar;19(1):41-6. doi: 10.3109/13506129.2011.638682. Epub 2011 Dec 8. Review.

35.

Current diagnosis of CIDP: the need for biomarkers.

Brannagan TH 3rd.

J Peripher Nerv Syst. 2011 Jun;16 Suppl 1:3-13. doi: 10.1111/j.1529-8027.2011.00298.x.

PMID:
21696490
36.

Experience with the Awaji Island modifications to the ALS diagnostic criteria.

Chen A, Weimer L, Brannagan T 3rd, Colin M, Andrews J, Mitsumoto H, Kaufmann P.

Muscle Nerve. 2010 Nov;42(5):831-2. doi: 10.1002/mus.21841.

PMID:
20928911
37.

Demyelinating neuropathy in patients with hepatitis C virus infection.

Chin RL, Sander HW, Brannagan TH 3rd, De Sousa E, Latov N.

J Clin Neuromuscul Dis. 2010 Jun;11(4):209-12. doi: 10.1097/CND.0b013e3181b701c1.

PMID:
20516810
38.

Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment?

Brannagan TH 3rd, Patterson SK.

Expert Rev Clin Immunol. 2010 May;6(3):319-21. doi: 10.1586/eci.10.23. No abstract available.

PMID:
20441416
39.

Therapeutic strategies for diabetic neuropathy.

Habib AA, Brannagan TH 3rd.

Curr Neurol Neurosci Rep. 2010 Mar;10(2):92-100. doi: 10.1007/s11910-010-0093-7. Review.

PMID:
20425233
40.

Differential gene expression in chronic inflammatory demyelinating polyneuropathy (CIDP) skin biopsies.

Lee G, Xiang Z, Brannagan TH 3rd, Chin RL, Latov N.

J Neurol Sci. 2010 Mar 15;290(1-2):115-22. doi: 10.1016/j.jns.2009.10.006. Epub 2009 Nov 17.

PMID:
19922956
41.

Small fiber neuropathy following vaccination for rabies, varicella or Lyme disease.

Souayah N, Ajroud-Driss S, Sander HW, Brannagan TH, Hays AP, Chin RL.

Vaccine. 2009 Dec 9;27(52):7322-5. doi: 10.1016/j.vaccine.2009.09.077. Epub 2009 Oct 4.

PMID:
19808027
42.

Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.

Donofrio PD, Berger A, Brannagan TH 3rd, Bromberg MB, Howard JF, Latov N, Quick A, Tandan R.

Muscle Nerve. 2009 Nov;40(5):890-900. doi: 10.1002/mus.21433. Review.

PMID:
19768755
43.

Demyelinating findings in typical and atypical chronic inflammatory demyelinating polyneuropathy: sensitivity and specificity.

De Sousa EA, Chin RL, Sander HW, Latov N, Brannagan TH 3rd.

J Clin Neuromuscul Dis. 2009 Jun;10(4):163-9. doi: 10.1097/CND.0b013e31819a71e1.

PMID:
19494726
44.

Current treatments of chronic immune-mediated demyelinating polyneuropathies.

Brannagan TH 3rd.

Muscle Nerve. 2009 May;39(5):563-78. doi: 10.1002/mus.21277. Review.

PMID:
19301378
45.

Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease.

Souayah N, Chin RL, Brannagan TH, Latov N, Green PH, Kokoszka A, Sander HW.

Eur J Neurol. 2008 Dec;15(12):1300-3. doi: 10.1111/j.1468-1331.2008.02305.x.

PMID:
19049545
46.

Non-length dependent small fibre neuropathy/ganglionopathy.

Gorson KC, Herrmann DN, Thiagarajan R, Brannagan TH, Chin RL, Kinsella LJ, Ropper AH.

J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):163-9. Epub 2007 Oct 2.

PMID:
17911181
47.

High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.

Gladstone DE, Golightly MG, Brannagan TH 3rd.

J Neuroimmunol. 2007 Oct;190(1-2):121-6. Epub 2007 Sep 14.

PMID:
17854912
48.

Rare myelin protein zero sequence variant in late onset CMT1B.

Souayah N, Seltzer WK, Brannagan TH, Chin RL, Sander HW.

J Neurol Sci. 2007 Dec 15;263(1-2):177-9. Epub 2007 Jun 28.

PMID:
17602703
49.

Anti-MAG/SGPG associated neuropathy does not commonly cause distal nerve temporal dispersion.

Gondim FA, De Sousa EA, Latov N, Sander HW, Chin RL, Brannagan TH.

J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):902-4. Epub 2007 Mar 12.

50.

Correlation of clinical and demyelinating features in patients with neuropathy of otherwise unknown etiology.

Goldfarb AR, Latov N, Brannagan TH 3rd, Chin RL, de Sousa EA, Sander HW.

Neurol Neurophysiol Neurosci. 2006 Dec 22:7.

PMID:
17260084

Supplemental Content

Loading ...
Support Center